This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
5 Most-Loved ETFs of Last Week
by Sweta Killa
Overall, ETFs pulled in a modest $260 million in capital for the week (ending May 5), bringing total inflows of $111.7 billion year to date.
Will ExOne (XONE) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
ExOne (XONE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ExOne (XONE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ExOne (XONE) delivered earnings and revenue surprises of -13.64% and 20.76%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
ExOne (XONE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
ExOne (XONE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: ExOne (XONE)
by Zacks Equity Research
ExOne (XONE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Will ExOne (XONE) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
ExOne (XONE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ExOne (XONE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ExOne (XONE) delivered earnings and revenue surprises of -10.53% and 0.80%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for ExOne (XONE)
by Zacks Equity Research
ExOne (XONE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Clean Energy Fuels' (CLNE) Q4 Earnings?
by Zacks Equity Research
Clean Energy Fuels' (CLNE) fourth-quarter earnings are expected to have benefited from increased acceptance of the ZeroNow Program, with more natural gas trucks hitting the road.
ExOne (XONE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
ExOne (XONE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Immersion (IMMR) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Though Immersion's (IMMR) Q4 revenues might have been negatively impacted by the pandemic, efficient cost management is likely to have aided the bottom line.
Daqo New Energy (DQ) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Daqo New Energy's (DQ) fourth-quarter results are expected to reflect the benefits of higher production and sales volumes.
ExOne (XONE) Soars 24.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ExOne (XONE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ExOne (XONE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ExOne (XONE) delivered earnings and revenue surprises of 5.00% and 37.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ExOne (XONE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
ExOne (XONE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ExOne (XONE) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
ExOne (XONE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
by Zacks Equity Research
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
Sealed Air (SEE) Stock Down 18% YTD: Will it Bounce Back?
by Zacks Equity Research
Sealed Air's (SEE) end markets are bearing the brunt of coronavirus pandemic. However, the company's restructuring actions will help negate the impact.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
ExOne (XONE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ExOne (XONE) delivered earnings and revenue surprises of 26.67% and 16.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ExOne (XONE) Q1 Earnings Expected to Decline
by Zacks Equity Research
ExOne (XONE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: ExOne (XONE) Q4 Earnings Expected to Decline
by Zacks Equity Research
ExOne (XONE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ExOne (XONE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ExOne (XONE) delivered earnings and revenue surprises of 6.25% and 8.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ExOne (XONE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ExOne (XONE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ExOne (XONE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ExOne (XONE) delivered earnings and revenue surprises of -4.55% and -1.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?